GTSM:4167

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. More Details


Snowflake Analysis

Flawless balance sheet with acceptable track record.

Share Price & News

How has Savior Lifetec's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 4167 is not significantly more volatile than the rest of TW stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 4167's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-7.2%

4167

-2.4%

TW Pharmaceuticals

2.5%

TW Market


1 Year Return

31.9%

4167

28.2%

TW Pharmaceuticals

31.6%

TW Market

Return vs Industry: 4167 exceeded the TW Pharmaceuticals industry which returned 28.2% over the past year.

Return vs Market: 4167 matched the TW Market which returned 31.6% over the past year.


Shareholder returns

4167IndustryMarket
7 Day-7.2%-2.4%2.5%
30 Day-18.9%-10.2%11.8%
90 Day-15.5%-21.6%22.9%
1 Year31.9%31.9%30.4%28.2%36.3%31.6%
3 Year-4.5%-4.5%34.3%27.1%59.7%41.8%
5 Year22.7%21.2%6.4%-1.6%136.2%94.8%

Long-Term Price Volatility Vs. Market

How volatile is Savior Lifetec's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Savior Lifetec undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: 4167 (NT$27.7) is trading below our estimate of fair value (NT$184.22)

Significantly Below Fair Value: 4167 is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: 4167 is poor value based on its PE Ratio (38.1x) compared to the TW Pharmaceuticals industry average (17.3x).

PE vs Market: 4167 is poor value based on its PE Ratio (38.1x) compared to the TW market (18.4x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 4167's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 4167 is overvalued based on its PB Ratio (2.6x) compared to the TW Pharmaceuticals industry average (2x).


Next Steps

Future Growth

How is Savior Lifetec forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

15.9%

Forecasted annual revenue growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: Insufficient data to determine if 4167's forecast earnings growth is above the savings rate (0.8%).

Earnings vs Market: Insufficient data to determine if 4167's earnings are forecast to grow faster than the TW market

High Growth Earnings: Insufficient data to determine if earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: 4167's revenue (15.9% per year) is forecast to grow faster than the TW market (11.3% per year).

High Growth Revenue: 4167's revenue (15.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 4167's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Savior Lifetec performed over the past 5 years?

41.5%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 4167 has high quality earnings.

Growing Profit Margin: 4167 became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 4167 has become profitable over the past 5 years, growing earnings by 41.5% per year.

Accelerating Growth: 4167 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 4167 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).


Return on Equity

High ROE: 4167's Return on Equity (6.3%) is considered low.


Next Steps

Financial Health

How is Savior Lifetec's financial position?


Financial Position Analysis

Short Term Liabilities: 4167's short term assets (NT$2.4B) exceed its short term liabilities (NT$554.7M).

Long Term Liabilities: 4167's short term assets (NT$2.4B) exceed its long term liabilities (NT$991.1M).


Debt to Equity History and Analysis

Debt Level: 4167's debt to equity ratio (18%) is considered satisfactory.

Reducing Debt: 4167's debt to equity ratio has reduced from 78.4% to 18% over the past 5 years.

Debt Coverage: 4167's debt is well covered by operating cash flow (43.8%).

Interest Coverage: 4167's interest payments on its debt are well covered by EBIT (7.9x coverage).


Balance Sheet


Next Steps

Dividend

What is Savior Lifetec current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 4167's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate 4167's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 4167's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 4167's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 4167's dividend in 3 years as they are not forecast to pay a notable one for the TW market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?


CEO

M. Ku

no data

Tenure

Dr. M. Sherry Ku, Ph.D. serves as the Chief Executive Officer at Savior Lifetec Corporation since 2014 and served as its Chairman since 2014 until 2018. Dr. Ku served as the Head of Early Pharmaceutical De...


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 11.3%.


Top Shareholders

Company Information

Savior Lifetec Corporation's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Savior Lifetec Corporation
  • Ticker: 4167
  • Exchange: GTSM
  • Founded: 2004
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: NT$8.263b
  • Shares outstanding: 298.30m
  • Website: https://www.saviorlifetec.com.tw/en/

Number of Employees


Location

  • Savior Lifetec Corporation
  • 29, Ke-Jhong Road
  • Chunan Chen
  • Miaoli
  • 35053
  • Taiwan

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
4167GTSM (Taipei Exchange)YesCommon StockTWTWDDec 2012

Biography

Savior Lifetec Corporation, a specialty injectable company, produces and supplies sterile APIs and finished dosage formulations. The company offers imipenem and cilastatin sodium, an antibacterial agent fo...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/01/23 08:43
End of Day Share Price2021/01/22 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.